Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate
Åsa Kolterud, Niko Välimäki, Heli Kuisma, Joonatan Patomo, Sini Ilves, Netta Mäkinen, Jaana Kaukomaa, Kimmo Palin, Eevi Kaasinen, Auli Karhu, Annukka Pasanen, Ralf Bützow, Oskari Heikinheimo, Helena Kopp Kallner, Lauri A. Aaltonen
Abstract
Precision medicine carries great potential for management of all tumor types. The aim of this retrospective study was to investigate if the two most common genetically distinct uterine fibroid subclasses, driven by aberrations in MED12 and HMGA2 genes, respectively, influence response to treatment with the progesterone receptor modulator ulipristal acetate. Changes in diameter and mutation status were derived for 101 uterine fibroids surgically removed after ulipristal acetate treatment. A significant difference in treatment response between the two major subclasses was detected. MED12 mutant fibroids had 4.4 times higher odds of shrinking in response to ulipristal acetate treatment as compared to HMGA2 driven fibroids (95% confidence interval 1.37-13.9; P = 0.013), and in a multivariate analysis molecular subclassification was an independent predictive factor. Compatible with this finding, gene expression and DNA methylation analyses revealed subclass specific differences in progesterone receptor signaling. The work provides a proof-of-principle that uterine fibroid treatment response is influenced by molecular subclass and that the genetic subclasses should be taken into account when evaluating current and future uterine fibroid therapies.